Yes, Lupron (leuprolide) is indicated with Erleada (apalutamide) for prostate cancer treatment.
Erleada must be administered with concurrent androgen deprivation therapy (ADT), which includes GnRH agonists like Lupron, unless the patient has undergone bilateral orchiectomy. 1
FDA-Mandated Combination Requirement
The FDA label for Erleada explicitly states: "Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy." 1 This is not optional—it is a required component of the approved regimen for both:
- Metastatic castration-sensitive prostate cancer (mCSPC)
- Non-metastatic castration-resistant prostate cancer (nmCRPC) 1
Clinical Practice Guideline Support
NCCN guidelines strongly recommend ADT in combination therapy for metastatic castration-sensitive disease, explicitly discouraging ADT monotherapy unless clear contraindications exist. 2 The guideline framework positions apalutamide (Erleada) as part of doublet therapy consisting of "ADT with an androgen receptor pathway inhibitor (ARPI; abiraterone, apalutamide, darolutamide, or enzalutamide)." 2
ESMO guidelines similarly document apalutamide + ADT as the evidence-based combination, citing the TITAN trial where apalutamide was studied specifically in combination with ADT, demonstrating:
- Median OS of 52.2 months (28.1-month gain over ADT alone)
- HR 0.65 for overall survival
- HR 0.48 for progression-free survival 3
Practical Implementation
The standard regimen is:
- Erleada 240 mg orally once daily
- Plus continuous GnRH agonist (Lupron/leuprolide) or GnRH antagonist
- Lupron is typically dosed as 7.5 mg IM monthly, 22.5 mg IM every 3 months, or 45 mg IM every 6 months 1
Critical Monitoring Consideration
One important caveat: A recent case report documented rare primary resistance to LHRH agonists where testosterone failed to suppress despite correct leuprolide administration. 4 The concomitant ARPI (apalutamide) masked this ADT failure by suppressing PSA despite elevated testosterone. Therefore, periodic testosterone monitoring remains essential to confirm adequate castration levels (<50 ng/dL), even when PSA appears well-controlled. 4
Bottom Line
Lupron is not just indicated—it is required for Erleada therapy per FDA labeling, unless surgical castration has been performed. The combination represents the evidence-based standard of care for both mCSPC and nmCRPC. 1, 3, 2